The results showed that the proportion of PMN-MDSCs in bone marrow, spleen and CD45+ cells from tumours was reduced, and the proportions of CD8 T-lymphocytes in spleens and CD45+ cells from tumours were increased dose-dependently after treatment with POG (Fig. 6d–e). This evidence concerns the gene PTPRC and neoplasm.